U.S., Feb. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07404436) titled 'Rivaroxaban in Idiopathic Membranous Nephropathy' on Feb. 05.
Brief Summary: Through a prospective, single-center, randomized controlled trial, we aim to determine the thromboprophylactic efficacy of rivaroxaban in patients with idiopathic membranous nephropathy (IMN). IMN patients at high risk of thrombosis and low risk of bleeding will be enrolled and randomly assigned to a rivaroxaban group or a control group (receiving warfarin). Prophylactic anticoagulation will be administered with rivaroxaban or warfarin accordingly. Over the 6 months following initiation of prophylactic anticoagulation, the incidence of the primary efficacy ...